On November 18, 2019, as a result of the advocacy of CLSA’s Washington, D.C. based team and the leadership of Congressman Lou Correa (D-Santa Ana), a California Democratic Delegation letter was sent to House Leadership urging swift action to repeal the medical device tax before the end of the year.
Participation in clinical trials has demonstrable effects on improved outcomes – they show us what works (and what doesn’t) in medicine. While fewer than 1 in 20 adult cancer patients in the U.S. have participated in a clinical trial, 60% of childhood cancer patients have participated. DOWNLOAD REPORT
Patrick Henning to lead CLSA’s Federal, State and Local Government Relations, Communications, Policy and Alliance Development Efforts on behalf of California’s life sciences sector
House overwhelmingly passes year-end spending deal that includes a permanent repeal of the 2.3% medical device tax, Senate likely to approve
Investment in R&D is the best way to ensure our nation is prepared to respond to health threats. New therapies do not come cheap. To go from concept to reality takes years of basic, clinical and translational science and research, all of which requires major financial investment, particularly from the private sector. DOWNLOAD REPORT
CLSA Disappointed by House Passage of H.R. 3, Legislation That Will Short-Circuit Treatments for Patients and California Innovation
On Dec. 12, the U.S. House is set to vote on H.R. 3, a bill that will have catastrophic consequences for patients and California’s life sciences sector. Learn why in this STAT News op-ed from CLSA CEO Mike Guerra.
The Governor’s Office of Business and Economic Development (GO-Biz) serves as California’s leader for job growth and economic development efforts. GO-Biz created the California Business Portal listing a variety of incentive and financing programs to encourage business development in California. DOWNLOAD INFOGRAPHIC
California leads the world in life sciences innovation. Premier research institutions combine with a unique entrepreneurial spirit to develop new technologies and therapies, attract investors and push the state’s economy to greater heights. It’s critical that we protect this pioneering activity to continue bringing hope to patients everywhere. See the highlights from our 2019 California Life Sciences Industry Report.
CLSA President & CEO Mike Guerra pens an op-ed in the San Francisco Chronicle on the urgency and need for Congress to repeal the medical device tax.